Clinical trials: Cerebral Circulatory Disorder
Intracerebral Hematoma
Stereotactic, Robot-assisted Intracerebral Hemorrhage Clot Evacuation
Non-traumatic intracerebral hemorrhage (ICH) affects approximately 100,000 Americans yearly. Up to 30-50% of ICH is fatal, and those patients who survive are often left with significant neurologic dysfunction.
- Trial name
- NCT03414307
- Testing
- Intracerebral catheter placement, Robot-assisted intracerebral catheter
- Where
- United States
- Sponsor
- Zimmer Biomet
Neurologic Disorder, Paralysis
COMMAND Early Feasibility Study: Implantable BCI to Control a Digital Device for People With Paralysis
The Synchron motor neuroprosthesis (MNP) is intended to be used in subjects with severe motor impairment, unresponsive to medical or rehabilitative therapy and a persistent functioning motor cortex.
- Conditions
- Neurologic Disorder, Paralysis, Paralysis; Stroke, Amyotrophic Lateral Sclerosis
- Trial name
- NCT05035823
- Testing
- Motor Neuroprosthesis (MNP)
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- Synchron Medical, Inc.
Stroke, Patent Foramen Ovale
Comparing PFO Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion
The objective of this study is to investigate whether percutaneous PFO closure with the Occlutech Flex II PFO Occluder is non-inferior to the AMPLATZER™ PFO Occluder and Gore® Cardioform Septal Occluder in closure of the PFO…
- Conditions
- Stroke, Patent Foramen Ovale, PFO
- Trial name
- OCCLUFLEX (NCT05069558)
- Testing
- Investigational PFO Closure Device, Standard of Care PFO Closure Device
- Where
- 48 sites in United States, Canada and 6 more
- Volunteers
- 450 people
- Sponsor
- Occlutech International AB
Ischemic Stroke
Rescues On Reperfusion Damage In Cerebral Infarction by Nelonemdaz
Efficacy and safety of Neu2000, a multi-target drug designed to prevent both NMDA receptor-mediated excitotoxicity and free radical toxicity, will be investigated in acute ischemic stroke patients receiving endovascular treatment…
- Trial name
- RODIN (NCT05041010)
- Testing
- Neu2000KWL group
- Where
- 24 sites in South Korea
- Volunteers
- 496 people
- Sponsor
- GNT Pharma
Hypoxic-Ischemic Encephalopathy, Hypoxia Neonatal
Feasibility and Safety of Umbilical Cord Blood Transfusion in the Treatment of Neonatal Cerebral Ischemia and Anemia
The study is to investigate the feasibility and safety of autologous umbilical cord blood transfusion to treat the newborn infants with presence of clinical indications of neonatal hypoxic-ischemia encephalopathy (HIE) and…
- Conditions
- Hypoxic-Ischemic Encephalopathy, Hypoxia Neonatal, Cerebral Ischemia of Newborn, Anemia, Neonatal
- Trial name
- NCT03352310
- Testing
- autologous umbilical cord blood (UCB), standard care
- Where
- Hong Kong
- Volunteers
- 40 people
- Sponsor
- Mononuclear Therapeutics Ltd.
Acute Ischemic Stroke
A Study of B2065 in Patients With Acute Ischemic Stroke
The goal of this clinical trial is to evaluate the safety of B2065, an allogeneic adipose-derived mesenchymal stromal cell (AD-MSC) injection. It will also assess whether B2065 works to treat acute ischemic stroke.
- Trial name
- NCT07371624
- Testing
- B2065
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function.
- Trial name
- NCT06383390
- Testing
- Retatrutide
- Where
- 742 sites in United States, Argentina and 25 more
- Volunteers
- 10,000 people
- Sponsor
- Eli Lilly and Company
Deep Vein Thrombosis Leg, Stroke (in Patients With Atrial Fibrillation)
A Healthy Volunteer Study to Investigate the Blood Concentrations, the Effect on Blood Clotting and the Safety of Multiple Doses of DPOC-4088 Tablets in Different Doses.
A study to investigate the concentrations of a new drug DPOC-4088 in blood, and to study the effect of this drug on blood clotting parameters.
- Trial name
- NCT01647620
- Testing
- DPOC-4088
- Where
- Belgium
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Diakron Pharmaceuticals
Intracranial Arteriosclerosis, Stenosis Artery
A Registry Study of Intracranial Atherosclerotic Stenosis Treatment by Intracranial Drug-eluting Stenting in China
The primary objective of this trial is to evaluate the long-term safety and efficacy of the NOVA intracranial drug-eluting stent system in "real world" patients with intracranial atherosclerotic stenosis.
- Conditions
- Intracranial Arteriosclerosis, Stenosis Artery, Drug-Eluting Stents, Intracranial Artery Stenosis
- Trial name
- NCT05692882
- Testing
- Drug-Eluting Stents
- Where
- 5 sites in China
- Volunteers
- 1,000 people
- Sponsor
- Sino Medical Sciences Technology Inc.
Stroke, Ischemic, Stroke Hemorrhagic
Evaluation of the Effectiveness and Safety of Keeogo™ Dermoskeleton in Subjects With Mobility Impairments Due to Stroke
A multi-site, interventional, non-comparative, single-arm trial to evaluate the safety of the Keeogo™ Dermoskeleton in subjects with hemiparesis due to ischemic or hemorrhagic stroke.
- Conditions
- Stroke, Ischemic, Stroke Hemorrhagic, Stroke, Hemiparesis
- Trial name
- NCT03986320
- Testing
- Keeogo™ Dermoskeleton
- Where
- 4 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- B-Temia, Inc.
Fabry Disease
Fabry Patient's Experience Of PegunigaLsidasE Alfa Monthly Infusion
Pegunigalsidase alfa (PRX-102) is a long-term enzyme replacement therapy design for the treatment of patients with Fabry disease.
- Trial name
- PEOPLE (NCT05186324)
- Testing
- Interview
- Where
- 12 sites in United States, Belgium and 3 more
- Volunteers
- 23 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Acute Ischemic Stroke
ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo
A randomized, double blind, multicenter, multinational, placebo controlled, parallel group, single dose, adaptive phase II/III study.
- Trial name
- ACTISAVE (NCT05070260)
- Testing
- Intravenous glenzocimab (ACT017) 1000 mg
- Where
- 10 sites in United States, Germany
- Volunteers
- 438 people
- Sponsor
- Acticor Biotech
Ischemic Stroke, Tandem Occlusion
Safety, Tolerability and Efficacy of Adjunctive TBO-309 in Reperfusion for Stroke With Tandem Occlusion
Co-STAR is a multicenter, prospective, open-label, Bayesian Optimal Phase 2 (BOP2) trial that aims to assess the safety and efficacy of adjunctive intravenous TBO-309 in Acute Ischaemic Stroke (AIS) patients with tandem occlusion…
- Trial name
- Co-STARS (NCT06813651)
- Testing
- TBO-309: 60 mg, TBO-309: 120 mg, TBO-309: 30 mg
- Where
- 2 sites in Australia
- Volunteers
- 78 people
- Sponsor
- ThromBio Pty. Ltd.
Aneurysmal Subarachnoid Hemorrhage
Clazosentan in Aneurysmal Subarachnoid Hemorrhage
The aim of this study is to demonstrate that clazosentan, administered as a continuous intravenous infusion at either 5 mg/h or 15 mg/h until Day 14 post aneurysmal subarachnoid hemorrhage (aSAH), reduces the incidence of…
- Trial name
- CONSCIOUS-3 (NCT00940095)
- Testing
- Clazosentan 5 m/h, Clazosentan 15 mg/h
- Where
- 145 sites in United States, Argentina and 26 more
- Volunteers
- 577 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Ischemic Stroke
Systematic Evaluation of Patients Treated With Stroke Devices for Acute Ischemic Stroke (STRATIS) Registry
The purpose of this registry is to assess clinical outcomes, and different factors that may affect these clinical outcomes such as systems of care, associated with the use of Covidien market-released neurothrombectomy devices…
- Trial name
- NCT02239640
- Where
- 55 sites in United States
- Volunteers
- 984 people
- Sponsor
- Medtronic Neurovascular Clinical Affairs
Fabry Disease
Study of the Safety and Biologic Activity of AL01211 in Treatment Naive Males With Classic Fabry Disease
This is a Phase II, open-label study designed to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of AL01211 in male subjects with classic Fabry disease who have never received any treatment (eg.
- Trial name
- NCT06114329
- Testing
- AL01211
- Where
- 6 sites in China
- Volunteers
- 16 people
- Sponsor
- AceLink Therapeutics, Inc.
Epilepsy, Dravet Syndrome
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies
The purpose of this study is to investigate the effect on the frequency of all seizures (convulsive and drop) in participants treated with TAK-935 compared to placebo.
- Conditions
- Epilepsy, Dravet Syndrome, Lennox-Gastaut Syndrome
- Trial name
- ELEKTRA (NCT03650452)
- Testing
- TAK-935
- Where
- 44 sites in United States, Australia and 6 more
- Volunteers
- 141 people
- Sponsor
- Takeda
Arteriovenous Malformations
Apollo™ Onyx™ Delivery Microcatheter Post Market Safety Study
The purpose of this study is to evaluate the safety of the Apollo™ Onyx™ Delivery Microcatheter used for delivery of the Onyx™ Liquid Embolic System during brain arteriovenous malformation (AVM) embolization procedures.
- Trial name
- NCT02378883
- Testing
- Apollo™ Onyx™ Delivery Micro Catheter
- Where
- 2 sites in United States
- Volunteers
- 112 people
- Sponsor
- Medtronic Neurovascular Clinical Affairs
Cerebral Infarction
Effect of Sarpogrelate on Platelet Aggregation in Patients With Cerebral Infarction: Dose-responsive Clinical Pharmacology Study
Sarpogrelate is an antiplatelet agent that decreases 5-hydroxytryptamine( 5-HT )levels in platelets via blockade of 5-HT2 receptors, has been used in atherosclerotic peripheral arterial disease.
- Trial name
- NCT00147303
- Testing
- MCI-9042
- Volunteers
- 46 people
- Sponsor
- Tanabe Pharma Corporation
Acute Ischemic Stroke
Hybernia Medical Post-Mechanical Thrombectomy Cerebral Cooling in Stroke
Reducing the temperature of tissue or organs (hypothermia) produces a protective state, through multiple molecular mechanisms, against adverse effects that arise from disrupted organ blood flow, e.g.
- Trial name
- Post-MECC (NCT06634303)
- Testing
- Brain cooling
- Where
- Spain
- Volunteers
- 8 people
- Sponsor
- Hybernia Medical
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.